Genlink Pharma Solutions has informed about submission of financial results along with limited review report for the half year ended 30th September, 2019 and certificate by debenture trustee pursuant to regulation 52 of SEBI (LODR), 2015.
The above information is a part of company’s filings submitted to BSE.